€2.3m · Seed · Healthtech · Konstanz, Germany
Konstanz-based medtech Eversion has raised €2.3m in a Seed II round co-led by Kammerer Holding and the Chancenkapitalfonds of Kreissparkasse Biberach, with participation from other venture funds, family offices, existing investors and business angels. According to Eversion's legal adviser, the capital will expand sales and marketing, grow a partner network of doctors, therapists and medical-supply stores, and accelerate adoption of its personalised insoles.
Turning an at-home gait test into a manufactured device
Eversion's process begins with sensor insoles and a smartphone app. Users measure how they move in their everyday shoes over a two-week period; a biomechanical 3D model then produces an individual load profile, which is used to manufacture what Eversion calls a 0° insole. The company says the product differs from conventional supportive insoles by correcting the measured load from underneath while leaving the top surface flat, so the foot remains active.
That workflow combines a temporary diagnostic kit with a made-to-order physical product. It also lets Eversion gather measurements in the shoes and routines a customer actually uses, rather than relying only on a short clinic assessment. The commercial constraint is equally physical: each customer still needs a dependable measurement, interpretation and manufacturing process. Funding sales without maintaining that delivery chain would create demand faster than the company can fulfil it.
Distribution and reimbursement are part of the route to scale
At the time of the round, Eversion reported more than 1,500 customers, CE certification as a medical device and reimbursement through statutory health insurers when the product is paired with an eligible prevention course. Its current reimbursement guidance explains that statutory customers complete a certified online course and submit the participation certificate and invoice, while privately insured customers can seek reimbursement with a prescription, subject to their tariff.
This makes the planned partner network more than a marketing channel. Doctors, therapists and medical-supply stores can help Eversion build trust around a product that sits between consumer purchase and regulated healthcare, while reimbursement can lower the customer's effective out-of-pocket cost. The round's execution test is whether Eversion can make those routes repeatable: partner referrals must convert into completed measurements and manufactured insoles, and payer access must translate into sustained use rather than one-off trial.
